We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-13%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$515M
AUM Growth
-$122M
Cap. Flow
+$31.4M
Cap. Flow %
6.1%
Top 10 Hldgs %
68.79%
Holding
51
New
3
Increased
5
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$17.3M
2
IOBT
IO Biotech
IOBT
+$10.8M
3
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$9.99M
4
LENZ
LENZ Therapeutics
LENZ
+$4.97M
5
VTVT icon
vTv Therapeutics
VTVT
+$2.2M

Top Sells

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$4.02M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.28M
3
TIL icon
Instil Bio
TIL
+$2.96M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.96M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 95.86%
2 Financials 1.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
26
Novavax
NVAX
$1.31B
$3.88M 0.75%
27,144
-3,016
-10% -$518K
DBTX
27
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$3.84M 0.75%
826,422
– –
BOLT icon
28
Bolt Biotherapeutics
BOLT
$7.78M
$3.61M 0.7%
36,873
– –
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.96B
$3.45M 0.67%
345,293
+45,000
+15% +$506K
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$3.41M 0.66%
202,500
– –
BLSA
31
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.94M 0.57%
300,000
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.6M 0.5%
711,039
– –
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$2.33M 0.45%
100,000
– –
EQ icon
34
Equillium
EQ
$133M
$2.32M 0.45%
615,541
-122,635
-17% -$663K
IMCR icon
35
Immunocore
IMCR
$1.73B
$2.19M 0.43%
64,000
– –
TERN
36
DELISTED
Terns Pharmaceuticals
TERN
$2.04M 0.4%
289,068
– –
SRZN icon
37
Surrozen
SRZN
$297M
$1.93M 0.37%
20,000
– –
ALLK
38
DELISTED
Allakos
ALLK
$1.69M 0.33%
172,089
– –
ALLK
39
CALL
DELISTED
Allakos
ALLK
$1.65M 0.32%
168,200
– –
VTVT icon
40
vTv Therapeutics
VTVT
$139M
$1.63M 0.32%
+40,888
New +$2.2M
BCEL
41
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.2M 0.23%
396,835
– –
KLRS
42
Kalaris Therapeutics
KLRS
$96.8M
$1.06M 0.21%
3,580
– –
KRON
43
DELISTED
Kronos Bio
KRON
$1.06M 0.21%
78,131
– –
BNTX icon
44
BioNTech
BNTX
$23.5B
$1.04M 0.2%
4,031
-1,727
-30% -$473K
VTGN icon
45
VistaGen Therapeutics
VTGN
$12.8M
$953K 0.18%
16,288
– –
ODT
46
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$946K 0.18%
700,421
– –
RCKT icon
47
Rocket Pharmaceuticals
RCKT
$394M
$885K 0.17%
40,550
– –
KALA icon
48
KALA BIO
KALA
$14.5M
$727K 0.14%
241
– –
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$242K 0.05%
13,669
– –
ATXS
50
DELISTED
Astria Therapeutics
ATXS
$135K 0.03%
25,000
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2021 Portfolio in Review

As of Q4 2021, Samsara BioCapital held 51 positions worth $515M, down 19% from $637M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Samsara BioCapital deployed $31.4M of net new capital in Q4 2021, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was IO Biotech: 1,120,437 shares worth $7.17M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Recursion Pharmaceuticals, an estimated $4.02M trimmed.

  • Samsara BioCapital's largest Q4 2021 buy was IO Biotech: 1,120,437 shares worth $7.17M.
  • Samsara BioCapital added most to Chinook Therapeutics, Inc. Common Stock in Q4 2021, an estimated $17.3M increase.
  • Samsara BioCapital's biggest Q4 2021 reduction was Recursion Pharmaceuticals, cutting an estimated $4.02M.
  • Samsara BioCapital's ten largest holdings make up 69% of its $515M portfolio in Q4 2021.
  • Samsara BioCapital opened 3 new positions and closed 0 in Q4 2021.
  • Samsara BioCapital's portfolio value fell 19% quarter-over-quarter to $515M.

Based on Samsara BioCapital's 13F filing for Q4 2021, filed 14 Feb 2022.